Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Limiting tumor seeding as a therapeutic approach for metastatic disease.

Worrede A, Meucci O, Fatatis A.

Pharmacol Ther. 2019 Jul;199:117-128. doi: 10.1016/j.pharmthera.2019.03.007. Epub 2019 Mar 12. Review.

2.

Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy.

Qian C, Worrede-Mahdi A, Shen F, DiNatale A, Kaur R, Zhang Q, Cristofanilli M, Meucci O, Fatatis A.

Mol Cancer Res. 2018 Dec;16(12):1844-1854. doi: 10.1158/1541-7786.MCR-18-0302. Epub 2018 Aug 16.

3.

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J.

Cell. 2018 Aug 23;174(5):1200-1215.e20. doi: 10.1016/j.cell.2018.07.015. Epub 2018 Aug 9.

4.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

5.

Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.

Shahriari K, Shen F, Worrede-Mahdi A, Liu Q, Gong Y, Garcia FU, Fatatis A.

Oncogene. 2017 May 18;36(20):2846-2856. doi: 10.1038/onc.2016.436. Epub 2016 Dec 19.

6.

v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG.

Cancer Res. 2016 Nov 15;76(22):6723-6734. doi: 10.1158/0008-5472.CAN-15-3327. Epub 2016 Sep 15.

7.

Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells.

Shen F, Zhang Y, Jernigan DL, Feng X, Yan J, Garcia FU, Meucci O, Salvino JM, Fatatis A.

Mol Cancer Res. 2016 Jun;14(6):518-27. doi: 10.1158/1541-7786.MCR-16-0013. Epub 2016 Mar 21.

8.

Mitochondrial mass and DNA repair in breast cancer stem cells.

Pestell RG, Fatatis A, Jiao X.

Oncotarget. 2015 Nov 17;6(36):38442-3. doi: 10.18632/oncotarget.6305. No abstract available.

9.

A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process.

Wurth R, Tarn K, Jernigan D, Fernandez SV, Cristofanilli M, Fatatis A, Meucci O.

Transl Oncol. 2015 Oct;8(5):358-67. doi: 10.1016/j.tranon.2015.07.002.

10.

Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT.

Am J Pathol. 2015 Sep;185(9):2505-22. doi: 10.1016/j.ajpath.2015.04.026.

11.

PKCε Is an Essential Mediator of Prostate Cancer Bone Metastasis.

Gutierrez-Uzquiza A, Lopez-Haber C, Jernigan DL, Fatatis A, Kazanietz MG.

Mol Cancer Res. 2015 Sep;13(9):1336-46. doi: 10.1158/1541-7786.MCR-15-0111. Epub 2015 May 28.

12.

Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.

Ferrari-Amorotti G, Chiodoni C, Shen F, Cattelani S, Soliera AR, Manzotti G, Grisendi G, Dominici M, Rivasi F, Colombo MP, Fatatis A, Calabretta B.

Neoplasia. 2014 Dec;16(12):1047-58. doi: 10.1016/j.neo.2014.10.006.

13.

CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.

14.

Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells.

Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O'Connell M, Jernigan D, Fatatis A, Languino LR, Bosari S, Altieri DC.

J Clin Invest. 2013 Jul;123(7):2907-20. doi: 10.1172/JCI67841. Epub 2013 Jun 10.

15.

Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions.

Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR.

Cancer Res. 2013 May 15;73(10):3155-67. doi: 10.1158/0008-5472.CAN-12-3266. Epub 2013 Mar 27.

16.

Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.

Liu Q, Russell MR, Shahriari K, Jernigan DL, Lioni MI, Garcia FU, Fatatis A.

Cancer Res. 2013 Jun 1;73(11):3297-305. doi: 10.1158/0008-5472.CAN-12-3970. Epub 2013 Mar 27.

17.

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21.

18.

The chemokine receptor CX₃CR1 is directly involved in the arrest of breast cancer cells to the skeleton.

Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O, Fatatis A.

Breast Cancer Res. 2011 Sep 20;13(5):R91. doi: 10.1186/bcr3016.

19.

Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.

Liu Q, Jernigan D, Zhang Y, Fatatis A.

Chin J Cancer. 2011 Sep;30(9):612-9. doi: 10.5732/cjc.011.10225. Review.

20.

Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.

Russell MR, Liu Q, Fatatis A.

Clin Cancer Res. 2010 Oct 15;16(20):5002-10. doi: 10.1158/1078-0432.CCR-10-1863. Epub 2010 Sep 2.

21.

Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.

Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Cell Cycle. 2010 Jun 15;9(12):2412-22. Epub 2010 Jun 15.

PMID:
20562527
22.

The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.

Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Cell Cycle. 2010 May 15;9(10):1960-71. Epub 2010 May 15.

PMID:
20495363
23.

The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A.

Cancer Res. 2010 May 15;70(10):4195-203. doi: 10.1158/0008-5472.CAN-09-4712. Epub 2010 May 4.

24.

Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons.

Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O.

J Biol Chem. 2010 Apr 2;285(14):10563-71. doi: 10.1074/jbc.M109.035477. Epub 2010 Feb 2.

25.

Osteoblasts modulate Ca2+ signaling in bone-metastatic prostate and breast cancer cells.

D'Ambrosio J, Fatatis A.

Clin Exp Metastasis. 2009;26(8):955-64. doi: 10.1007/s10585-009-9286-3. Epub 2009 Sep 21.

PMID:
19768662
26.

The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.

Russell MR, Jamieson WL, Dolloff NG, Fatatis A.

Oncogene. 2009 Jan 22;28(3):412-21. doi: 10.1038/onc.2008.390. Epub 2008 Oct 13.

PMID:
18850002
27.

CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism.

Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O, Fatatis A.

Cancer Res. 2008 Mar 15;68(6):1715-22. doi: 10.1158/0008-5472.CAN-07-1315.

28.
29.

Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor.

Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A.

Oncogene. 2005 Oct 13;24(45):6848-54.

30.

Regulation of neuronal P53 activity by CXCR 4.

Khan MZ, Shimizu S, Patel JP, Nelson A, Le MT, Mullen-Przeworski A, Brandimarti R, Fatatis A, Meucci O.

Mol Cell Neurosci. 2005 Sep;30(1):58-66.

31.

Apoptotic and antiapoptotic effects of CXCR4: is it a matter of intrinsic efficacy? Implications for HIV neuropathogenesis.

Khan MZ, Brandimarti R, Patel JP, Huynh N, Wang J, Huang Z, Fatatis A, Meucci O.

AIDS Res Hum Retroviruses. 2004 Oct;20(10):1063-71.

32.
33.

Regulation of cell cycle proteins by chemokine receptors: A novel pathway in human immunodeficiency virus neuropathogenesis?

Brandimarti R, Khan MZ, Fatatis A, Meucci O.

J Neurovirol. 2004;10 Suppl 1:108-12. Review.

34.

The chemokine receptor CXCR4 regulates cell-cycle proteins in neurons.

Khan MZ, Brandimarti R, Musser BJ, Resue DM, Fatatis A, Meucci O.

J Neurovirol. 2003 Jun;9(3):300-14.

35.

Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival.

Meucci O, Fatatis A, Simen AA, Miller RJ.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8075-80. Erratum in: Proc Natl Acad Sci U S A 2001 Dec 18;98(26):15393.

36.
37.

Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity.

Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14500-5.

38.

Effects of histamine on intracellular calcium transients recorded with Fura-2 in renal pacemaker cells in guinea pig.

Moss J, Yuan CS, Fatatis A, Attele A.

Inflamm Res. 1997 Mar;46(Suppl 1):95-6. doi: 10.1007/s000110050111. No abstract available.

PMID:
27518021
39.

Effects of histamine on intracellular calcium transients recorded with Fura-2 in renal pacemaker cells in guinea pig.

Moss J, Yuan CS, Fatatis A, Attele A.

Inflamm Res. 1997 Mar;46 Suppl 1:S95-6. No abstract available.

PMID:
9098783
41.

Developmental regulation of the toxin sensitivity of Ca(2+)-permeable AMPA receptors in cortical glia.

Meucci O, Fatatis A, Holzwarth JA, Miller RJ.

J Neurosci. 1996 Jan 15;16(2):519-30.

43.

Role of the Na(+)-Ca2+ and Na(+)-H+ antiporters in prolactin release from anterior pituitary cells in primary culture.

Di Renzo G, Amoroso S, Bassi A, Fatatis A, Cataldi M, Colao AM, Lombardi G, Annunziato L.

Eur J Pharmacol. 1995 Dec 27;294(1):11-5.

PMID:
8788411
44.

Appearance of depolarization- and maitotoxin-induced [Ca2+]i elevation in single LAN-1 human neuroblastoma cells on exposure to retinoic acid.

Fatatis A, Bassi A, Iannotti E, Caso N, Mita GD, Di Renzo G, Annunziato L.

J Neurochem. 1994 Nov;63(5):1900-7.

PMID:
7523602
45.
46.

Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors.

Fatatis A, Holtzclaw LA, Avidor R, Brenneman DE, Russell JT.

Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2036-40.

47.

Immortalization of a cell line showing some characteristics of the oligodendrocyte phenotype.

Russo T, Mogavero AR, Ammendola R, Mesuraca M, Fiore F, Fatatis A, Salvatore G, Cimino F.

Neurosci Lett. 1993 Sep 3;159(1-2):159-62.

PMID:
8264960
48.

Type IV collagen stimulates an increase in intracellular calcium. Potential role in tumor cell motility.

Savarese DM, Russell JT, Fatatis A, Liotta LA.

J Biol Chem. 1992 Oct 25;267(30):21928-35.

49.
50.

LAN-1 human neuroblastoma cells are provided of endothelin-1 receptors linked to [Ca++]i elevation.

Fatatis A, Bassi A, Mita G, Di Renzo GF, Annunziato L.

Funct Neurol. 1992 May-Jun;7(3):239-42.

PMID:
1323509

Supplemental Content

Loading ...
Support Center